

REMARKS

In the Office Action, the Examiner set forth six groups of claims alleging that each invention or group of inventions are distinct inventions. The groups set forth by the Examiner are noted below:

Group I, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form imidazopyrimidines, method of treatments and compositions thereof, classified in class 544, subclass 350 and class 514, subclass 249.

Group II, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form imidazopyridines, method of treatments and compositions thereof, classified in class 546, subclass 121 and class 514, subclass 300.

Group III, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form imidazothiadiazoles, method of treatments and compositions thereof, classified in class 548, subclass 126 and class 514, subclass 363.

Group IV, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form imidazothiazoles, method of treatments and compositions thereof, classified in class 548, subclass 154 and class 514, subclass 368.

Group V, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form imidazoimidazoles, method of treatments and compositions thereof, classified in class 548, subclass 303.1 and class 514, subclass 393.

Group VI, Claims 1-15, drawn to compounds of formula (I), wherein R^4 and R^6 form any other fused heteroaromatic bicycle not covered by groups I-V, method of treatments and compositions thereof, the classification dependent on the heteroaromatic group elected.

The Examiner alleges that the claims listed in each of the groups are distinct inventions because they claim compounds have diverse chemical structures, different chemical properties, modes of action, different effects and reactive conditions. The examiner also alleges that the level of skill in the art is not such that one invention would be obvious over the other, i.e., they are patentable over each other.

Applicants respectfully traverse this rejections and request reconsideration. However, in order to advance the prosecution of this case, Applicants select the invention of Group I and elect the compound 6[2-(6-methyl-pyridin-2-yl)-imidazol[1,2-a]pyrimidin-3-yl]-quinoline as the species to first be examined. Antecedent basis for this compound is found at Example 5 of the application as filed. Claims 1, 4, 9, 12, and 13 have been amended to delete non-elected subject matter. Claim 15 has been previously withdrawn. Applicants reserve the right to prosecute the non-elected subject matter in subsequent applications.


Applicants invite the Examiner to call the undersigned if a telephone interview would advance the prosecution.

Finally, the undersigned notes that subsequent correspondence should be addressed to:

Rosanne Goodman
Pfizer Inc.
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-4182

Respectfully submitted,

Dated: November 27, 2006


Rosanne Goodman
Registration No. 32,534
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-4182
Facsimile: (734) 622-1553